#romosozumab

🔰 International Speaker Program BUILD BONE FIRST

🔺 "Understanding romosozumab through Clinical experience

🗓️ Date : Sunday 28 April 2024 🕠 Time : 5:30pm IST

👨‍💻 Click here to register : https://tinyurl.com/OrthoTV-Evenity

🆓 Registration is free but Mandatory for all

👨‍⚕️ Dr. Paul D. Miller M.D., HDSc (HON) Distinguished Clinical Professor of Medicine University of Colorado Health Sciences Center Medical Director, Colorado Center for Bone Health, Lakewood

👨‍⚕️ Dr. Felicia Cosman M.D., Professor of Medicine Columbia University, New York, NY Adjunct Senior Scientist (Courtesy) in the Metabolic Bone Disease Service, Hospital for Special Surgery, NY Co-Editor-in-Chief, Osteoporosis International

✅ PROGRAM AGENDA BUILDING BETTER BONES with Romosozumab

🔘 Topic:• Introduction and context setting - Chairperson • Optimising bone health for the very high risk patient with romosozumab - Dr. Felicia Cosman • Chronic kidney disease and Osteoporosis: Use of romosozumab and denosumab - Dr. Paul Miller • Panel discussion - Risk stratification, guidelines and positioning romosozumab in India, Clinical experience sharing and Q & A - Moderator and all other panel members

• 📤Vote of thanks - DRL team

🤝OrthoTV Team: Dr Ashok Shyam, Dr Neeraj Bijlani

📺 Streaming live on OrthoTV www.orthotvonline.com

🔰 International Speaker Program BUILD BONE FIRST

🔺 "Understanding romosozumab through Clinical experience

🗓️ Date : Sunday 28 April 2024 🕠 Time : 5:30pm IST

👨‍💻 Click here to register : https://tinyurl.com/OrthoTV-Evenity

🆓 Registration is free but Mandatory for all

👨‍⚕️ Dr. Paul D. Miller M.D., HDSc (HON) Distinguished Clinical Professor of Medicine University of Colorado Health Sciences Center Medical Director, Colorado Center for Bone Health, Lakewood

👨‍⚕️ Dr. Felicia Cosman M.D., Professor of Medicine Columbia University, New York, NY Adjunct Senior Scientist (Courtesy) in the Metabolic Bone Disease Service, Hospital for Special Surgery, NY Co-Editor-in-Chief, Osteoporosis International

✅ PROGRAM AGENDA BUILDING BETTER BONES with Romosozumab

🔘 Topic:• Introduction and context setting - Chairperson • Optimising bone health for the very high risk patient with romosozumab - Dr. Felicia Cosman • Chronic kidney disease and Osteoporosis: Use of romosozumab and denosumab - Dr. Paul Miller • Panel discussion - Risk stratification, guidelines and positioning romosozumab in India, Clinical experience sharing and Q & A - Moderator and all other panel members

• 📤Vote of thanks - DRL team

🤝OrthoTV Team: Dr Ashok Shyam, Dr Neeraj Bijlani

📺 Streaming live on OrthoTV www.orthotvonline.com

Romosozumab, Obat Baru untuk Osteoporosis yang Beresiko Fraktur

farmasetika.com – Osteporosis atau yang lebih dikenal dengan pengeroposan tulang merupakan keadaan terjadinya penurunan kepadataan tulang sehingga tulang akan keropos bahkan bisa menyebabkan patah (fraktur).  Banyak faktor penyebab terjadinya osteoporosis yaitu usia, menopause, konsumsi alkohol, masalah hormonal, kurangnya asupan kalsium dan lainnya. Jika dibandingkan dengan pria, penelitian dari

U.S. FDA Accepts Biologics License Application for Romosozumab, Amgen and UCB Announce

Sept. 26, 2016

Amgen and UCB have announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab. It is an investigational monoclonal antibody for treating osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab works by binding and hindering the activity of the protein sclerostin, naturally…